Shift Bioscience
Shift Bioscience is a Cellular Reprogramming & Rejuvenation company founded in 2017 and based in Cambridge, United Kingdom. It has raised $16M in total funding, most recently a Seed.
Shift Bioscience was founded in 2017 by CEO Daniel Ives and CSO Brendan Swain, based at the Gurdon Institute in Cambridge, UK. The company pairs machine learning with large-scale multiomic datasets and 'aging clock' models to screen thousands of candidate genes for ones that reverse cellular aging without triggering the dangerous pluripotency pathways associated with the full Yamanaka-factor cocktail. In June 2025 it published a preprint reporting SB000, described as the first single-gene intervention to rejuvenate cells across multiple germ layers with efficacy rivaling the Yamanaka factors, restoring younger profiles at both the methylome and transcriptome levels without evidence of pluripotency. Shift has raised roughly $16 million (about £12.5M seed led by BGF), with F-Prime Capital, Kindred Capital, and Jonathan Milner among backers.
A single-gene rejuvenation factor could be far safer and more deliverable as a therapy than the multi-factor reprogramming cocktails the field has relied on.
shiftbioscience.com ↗·Cellular Reprogramming & Rejuvenation·
United Kingdom·private 
